Loading...
High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment
The impact of drug–drug interactions (DDI) between ritonavir-boosted lopinavir (LPV-r) to treat patients with coronavirus disease 2019 (COVID-19) and commonly used drugs in clinical practice is not well-known. Thus, we evaluated the rate and severity of DDI between LPV-r for COVID-19 treatment and c...
Na minha lista:
| Udgivet i: | Sci Rep |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group UK
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708981/ https://ncbi.nlm.nih.gov/pubmed/33262433 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-78029-3 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|